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and 2/2 other T-cell lymphomas are alive and disease free).
Patients in CR or PR had a better OS (18/23) compared with
those patients with persistent or progressive disease at time
of transplant (0/5). 11/29 patients died (9 from relapse and 2
from treatment related mortality).
Conclusions: HSCT offers the possibility of cure for patients
with NHL, especially for patients with ALCL and for those
patients that have a good response to re-induction therapy
prior to transplant. Relapsed disease post-transplant remains
a major challenge for patients with LL and for patients
transplanted with non-responsive disease. Post transplant
therapies to target residual disease should be evaluated in
these patients.280
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Introduction: Infections with NTM species are reported in
immunocompromised patients (pts) post-HCT with little
information on associated risk factors. In HIV+ pts, routine
prophylaxis is indicated for those with CD4 counts of 100-
200cells/uL. We hypothesize CD4 counts 200 as a possible
risk factor for development of NTM infection in the pediatric
alloHCT setting. We report our center’s experience with NTM
infections to help identify risk factors, clinical signiﬁcance
and need for prophylactic therapy.
Methods: Pts 21 years undergoing HCT from 2001 to 2014
were included. Deﬁnition of NTM infection: Positive culture
for NTM species in blood, cerebrospinal ﬂuid (CSF), lungs, BM
or tissue. Only pts withMycobacterium Avium Complex (MAC)
infection were included. Controls (n¼19) were identiﬁed by
matching age, gender, and underlying disease. Descriptive
statistics was calculated and comparison between 2 groups
was carried with t-test for continuous variables and Fisher
exact test for categorical variables.
Results: Of 272 pts undergoing HCT, NTM was diagnosed in
11 pts with 17 HCT (autologous¼1; allogeneic¼16) per-
formed among these pts. Indications for HCT: malignant¼6
(55%), non-malignant¼5 (45%). Donor sources: sibling BM
(n¼3), sibling PB (n¼2), unrelated PB (n¼3) unrelated BM
(n¼3), or unrelated UCB (n¼5). Conditioning regimens:
myeloablative (n¼7), non-myeloablative (n¼6), no condi-
tioning (n¼3). Pts had MAC isolated from the following sites:
lungs (n¼5), CSF (n¼1), BM (n¼2), lymph node (n¼1), and
blood (n¼3). Median date from HCT to NTM diagnosis was
233 days (range: 15 to 724 days). Mean absolute CD4 count at
diagnosis was 137 +/- 143 cells/uL (1 unreported). All pts
began therapy with azithromycin, ethambutol, and rifabutin/
rifampin. Additive therapy included levoﬂoxacin (n¼3),
imipenem (n¼1), amikacin (n¼3), and gatiﬂoxacin (n¼1).
Treatment duration ranged from 53-459 days. Eight of 11 pts
had graft-vs-host disease (GVHD) with 75% (n¼6) diagnosedprior to the onset of NTM. Overall survival was 73%(n¼8).
Causes of death were: complications due to NTM, progres-
sive underlying disease, and pulmonary failure secondary to
chronic GVHD. Of the 8 surviving pts, 1 had recurrence, 5
cleared the infection, and 2 are in treatment.
No statistically signiﬁcant risk factors for NTM were
found, including presence of GVHD, CD4 count at diagnosis,
CMV viremia, or donor source. Similar results were obtained
when not controlling for these variables. No statistically
signiﬁcant difference was found between pts who developed
MAC infections and those that did not.
Discussion: These results were unable to identify low CD4
counts as a potential risk factor for NTM necessitating the
need for multicenter collaborations. NTM appears to be a
treatable disease, with the role of prophylaxis unclear. With
the extensive treatment duration, healthcare utilization costs
should also be evaluated.281
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Hematopoietic Stem Cell Transplantation (HSCT) plays an
important role in the treatment of children with Acute
Myeloid Leukemia (AML). Match related donor (MRD) and
Unrelated Cord Blood Transplantation (UCBT) for patients
who lack a sibling donor are the options of HSCT in our unit.
UCB offers the advantage of faster availability of banked
cryopreserved UCB units compared with unrelated bone
marrow grafts with similar results in survival. We report our
results of HSCT for AML. We analyzed 28 children receiving
allogeneic HSCT for AML, 17 UCBT and 11 HSCT from a MRD.
Cord blood units were selected with 1 or 2 HLA mismatch;
reduce intensity conditioning (RIC) in all except two UCBT
consists of ﬂudaradine andmelphalan. Conditioning for MRD
HSCT consists of BU16/Cy120. Graft vs host disease prophy-
laxis with cyclosporine/MTX for MRD HSCT and cyclo-
sporine/MMF o cyclosporine/methylprednisolone for UCBT.
Average for neutrophil recovery in UCBT and MRD HSCT was
21 and 19 days respectively, average for platelet recovery in
UCBT and MRD HSCT was 34 and 23 days respectively.
Transplant related mortality in UCBT and MRD HSCT 18% and
17% respectively, causes of death were relapse(5¼29%) grade
IV hepatic graft versus host disease(2) and bacterial sepsis(1)
for UCBT, causes of death in MRD HSCT were relapse (1¼9%)
cerebral infarction(1) and chronic graft versus host dis-
ease(1). With a median follow up of 1 year, overall survival
for entire cohort was 60.7%, overall survival for UCBT was
52.9% and 72.7% for MRD HSCT (p¼0.25). Despite being few
patients these results show no signiﬁcant difference in
overall survival between related donors and unrelated cord
blood. RIC with ﬂudarabine and melphalan is a promising
alternative in children; it shows an acceptable relapse rate
compared with other more toxic conditionings.282
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Table 1
No serotherapy ATG Alemtuzumab p value
ADV 5.8 (0-16.9)% 0 % 29.3 (5.1-53.5)% 0.056
CMV 5.8 (0-16.9)% 20 (0-44.8)% 34 (9.7-58.3)% 0.08
EBV 5.8 (0-16.9)% 18.2 (0-40.5)% 0% .25
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Unrelated cord blood transplant (UCBT) is an established
graft source for HSCT especially for minorities. Use of sero-
therapy such as anti-thymocyte globulin (ATG) and alemtu-
zumab is associated with delayed immune reconstitution,
leading to increased viral reactivation especially when the
donors are virus naïve. Therefore, we studied the impact of
serotherapy along with other factors on viral reactivation
(EBV, CMV, adenovirus (ADV)), GVHD, and transplant-related
mortality (TRM) at 100 days in pediatric patients after UCBT.
Statistics used were chi-squared test, and Kaplan-Meier cu-
mulative incidence (CI) with log-rank. For CI of viral reac-
tivation, patients were censored if they died or reached day
100 before viral reactivation. All patients had weekly GVHD
grading using Glucksberg criteria and weekly PCR for the 3
viruses. Reactivation was deﬁned as blood viral PCR>1000
copies/ml. This retrospective study evaluated 47 consecutive
UCBTs performed from 2006-2014. Median age was 3 years
(range 0-17). Diagnoses: leukemia (19), immunodeﬁciency
(10), hemoglobinopathy (7), bone marrow failure (6), meta-
bolic disorder (3), andhistiocytic disorder (2). 21 patients
received myeloablative conditioning (MAC) and 26 reduced-
intensity conditioning (RIC). Median degree of HLA matching
was 5/6 (4-6/6). Pre-transplant serotherapy was used in 30
patients (15alemtuzumab, 15 ATG) irrespective of HLA
matching. Median cell dose was 6.15x107(0.9e18.9x107)
TNC/kg. Among all variables evaluated, underlying diagnosis
was the only one associated with development of  grade 2
acute GVHD, occurring predominantly in leukemia patients
(p¼0.048). For viral reactivation, the conditioning regimen
inﬂuenced CMV reactivation, with signiﬁcantly more CMV
reactivations in MAC recipients (p ¼ 0.044), and more EBV
reactivations in RIC recipients (p ¼ 0.046). Conditioning
regimen did not inﬂuence ADV reactivation. For ADV, only
the type of serotherapy had a strong association with reac-
tivation, with more ADV infections in patients who received
alemtuzumab (p ¼ 0.044). No variable had a relationship
with TRM. We then explored the day 100 CI of viral reac-
tivation, by type of serotherapy (Table 1). There was a trend
towards higher CI of ADV reactivation in patients who
received alemtuzumab. We conclude that in pediatric UCBT
patients, while the impact of serotherapy on acute GVHD is
unclear, it does have a major impact on viral reactivation.
Speciﬁcally, alemtuzumab appears to have more impact on
ADV reactivation than ATG. While further data will be
collected on the morbidity and mortality associated with
these infections, novel therapies to treat viruses in the
context of serotherapy-treated UCBT recipients are needed.283
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Objective: Inherited bone marrow failure syndromes
(IBMFS) are a heterogeneous group of genetic disorders
characterized by bone marrow failure, congenital anomalies,
and an increased risk of malignant disease. Because of
phenotypic variability, diagnosis can be challenging for cli-
nicians. This study is aimed to develop a targeted panel-
based Next Generation Sequencing (NGS) pipeline to clinical
diagnosis in IBMFS patients.
Method: Agilent Haloplex method was used for target cap-
ture the IBMFS Library of known genes and related genes,
Illumina platformwas used for high-throughput sequencing,
sequencing data was aligned by NextGENe software, the
variants were ﬁltered and interpretation by the online tool
Ingenuity Variant Analysis, and Sanger sequencing was used
to conﬁrm the variations. 21 patients with suspected IBMFS
were studied and DNA frommembers of each pedigree were
collected for this study.
Results: More than 95% of the sequencing reads aligned to
human genome reference sequence and more than 85% of
the reads are in the target sequence. The 20 coverage area is
>95% and the uniformity is >85%. Of the 21 patients with
suspected IBMFS, pathogenic mutations have been identiﬁed
in 12 patients, including 6 cases with Fanconi anemia (FA), 2
cases of Dyskeratosis congenital (DC), 2 cases of Severe
congenital neutropenia (SCN), 1 case of Diamond-Blackfan
anemia (DBA), and 1 case of Shwachman-Diamond syn-
drome (SDS). After hematopoietic stem cell transplantation,
5 patients were successfully cured. Prenatal diagnosis has
been successfully performed in 3 families.
Conclusion: This study successfully established the target
panel sequencingmethod tomoleculardiagnosis of IBMFS. The
clinical results showed that our method can effectively detect
and identify pathogenic genes in monogenic disorders and to
provide a strong basis for completely cure and prenatal diag-
nosis, because the efﬁciency of captured target region is
excellent, the quality of sequencing data is reliable, and the
analysis by the bioinformatics software is very comprehensive.284
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